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PRECIS: A novel transgenic mouse model may offer an ideal system to study the 
pathogenesis of human multiple myeloma, an aggressive disease that remains relatively 
poorly managed. 
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Abstract 
 
 Multiple myeloma (MM) is a currently incurable neoplasm of 
terminally-differentiated B cells. The translocation and/or overexpression of c-MAF 
have been observed in human MM. Although c-MAF might function as an oncogene in 
human MM, there has been no report thus far describing the direct induction of MM by 
c-MAF overexpression in vivo. In this study, we have generated transgenic mice that 
express c-Maf specifically in the B cell compartment. Aged c-Maf transgenic mice 
developed B cell lymphomas with some clinical features that resembled those of MM, 
namely plasma cell expansion and hyperglobulinemia. Quantitative RT-PCR analysis 
demonstrated that Ccnd2 and Itgb7, which are known target genes of c-Maf, were 
highly expressed in the lymphoma cells. This novel transgenic mouse model of the 
human MM t(14;16)(q32;q23) chromosomal translocation should serve to provide new 
insight into the role of c-MAF in tumorigenesis. 
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Introduction 
    Multiple myeloma (MM) is an incurable neoplasm of terminally-differentiated B 
cells that is characterized by monoclonal expansion of malignant plasma cells. The 
common premalignant stage of MM is a monoclonal gammopathy of undetermined 
significance (MGUS), which progresses to MM at the rate of 1% of patients per year 
(1). Extensive genomic analysis has revealed that approximately 50% of patients with 
MGUS and MM have primary translocations in the clonal plasma cells that involve the 
immunoglobulin heavy chain (IGH) locus on chromosome 14q32 (2). Chromosomal 
translocations that involve the juxtaposition of the IGH locus with the loci for CYCLIN 
D1 (3), FGFR3 (4), or MMSET (5) result in the overexpression of these genes. It was 
first reported a decade ago that c-MAF is expressed at high levels in MM cells that 
carry the translocation t(14;16)(q32;q23), in which the IGH locus is fused with the 
c-MAF gene locus (6). In addition, c-MAF is overexpressed in 50% of MM cell lines 
and patients (7).  
      The maf proto-oncogene was identified originally within the genome of the 
avian musculoaponeurotic fibrosarcoma virus, AS42 (8). The product of the Maf gene 
and other members of the Maf family share a conserved basic-region leucine zipper 
(bZIP) motif that mediates dimer formation and DNA binding to the Maf recognition 
element (MARE) (9). Large Maf proteins, such as c-Maf, Mafb, Mafa/L-Maf/SMaf and 
Nrl, also contain an acidic domain that mediates transcriptional activation and plays a 
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key role in cellular differentiation (8-12). c-Maf encodes a T helper cell type 2 
(Th2)-specific transcription factor that activates the expression of interleukin (IL)-4 in T 
cells (13). c-Maf is also involved in the regulation of lens fiber cell differentiation 
(14-16). Recently, we have found that transgenic mice that express c-Maf specifically 
in the T-cell compartment develop T-cell lymphoma (17). Furthermore, 60% of human 
T-cell lymphomas, classified as angioimmunoblastic T-cell lymphomas, were found to 
overexpress c-MAF (17, 18).  
      On the basis of the above facts, we hypothesized that overexpression of c-Maf 
in the B cell lineage would enhance the development of an MM-like disease. In this 
study, we have generated c-Maf transgenic mice that overexpress c-Maf in the B-cell 
compartment, using the IgH promoter and Eμ enhancer. We found that these mice 
developed B cell lymphoma, which provided the first direct evidence that c-Maf can 
function as an oncogene in a murine model of the t(14;16)(q32;q23) translocation.  
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Materials and Methods  
 
Mice. We made two constructs for the Eμ c-Maf transgene (Fig. 1A). For construct-1, 
we used the Eμ enhancer and the VH promoter, as described previously (19). A 1.5-kb 
full-length cDNA that encoded the murine c-Maf protein was inserted into a vector that 
contained the VH promoter and Eμ enhancer. Construct-1 was injected into fertilized 
eggs from BDF1 mice to generate transgenic mice, and then backcrossed four times 
into C57BL/6J. For construct-2, the VH promoter, Eμ enhancer, and 3'Eκ enhancer 
were used. Construct-2 was injected into fertilized eggs from C57BL/6J mice to 
generate transgenic mice. Mice were maintained with a C57BL/6J genetic background 
in specific pathogen-free conditions in a Laboratory Animal Resource Center. All 
experiments were carried out according to the Guide for the Care and Use of 
Laboratory Animals at the University of Tsukuba.  
 
Southern hybridization analysis. High molecular weight DNA was prepared from 
the tail of each mouse, and 10 μg of this DNA was digested with EcoR I and Hind III, 
and then Southern hybridization was performed, as described previously (17). To 
investigate IgH gene rearrangement, DNA from the tail and other tissues was 
examined by Southern hybridization. DNA that had been digested with EcoR I was 
hybridized with the JH4 fragment, as described previously (20).  
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Isolation of mouse B220+ cells and RT-PCR to analyze transgene expression. 
B220+ splenic B cells were isolated using magnetic microbeads from Miltenyi Biotec 
(Gladbach, Germany). Total RNA was prepared from the B220+ splenic B cells of 10 
weeks old transgenic mice or their wild-type littermates using TRIzol reagent 
according to the manufacturerʼs instructions (Invitrogen, Carlsbad, CA). Total RNA (1 
µg) was reverse transcribed into cDNA using SuperScript III Reverse Transcriptase 
(Invitrogen), and 1 µl of this 20 µl reaction mixture was used for PCR. The c-Maf 
sequence was amplified using the primers 5'-CCTGCCGCTTCAAGAGGGTGC-3' and 
5'-TCGCGTGTCACACTCACATG-3', which yielded a 225-bp product. The sequence 
of hprt (hypoxanthine guanine phosphoribosyl transferase), which was used as a 
control, was amplified using the primers 5'-CAAACTTTGCTTTCCCTGGT-3' and 
5'-CAAGGGCATATCCAACAACA-3', which yielded a 250-bp product. 
 
Western blot analysis. Nuclear extracts were prepared from the B220+ splenic B 
cells of 10 weeks old transgenic or wild-type mice. The extracts were fractionated by 
size on a 10% SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride 
membrane (Fluoro Trans; Pall BioSupport Division, Port Washington, NY), and 
incubated with primary and secondary antibodies. To detect the c-Maf protein, a rabbit 
antibody against mouse c-Maf was used as the primary antibody and 
peroxidase-conjugated goat anti-rabbit IgG (Zymed Laboratories, San Francisco, CA) 
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was used as the secondary antibody. The anti-c-Maf antibody was kindly provided by 
Dr. Masaharu Sakai (University of Hokkaido, Sapporo, Japan). To normalize the 
results with respect to the amount of protein in each sample, a goat antibody against 
mouse Lamin B (Santa Cruz Biochemicals, Santa Cruz, CA) was used.  
 
Flow cytometry analysis. Single-cell suspensions were prepared from the spleen 
and the bone marrow of each mouse. Multicolor flow cytometric analysis was 
performed using an LSR Flow Cytometer and CellQuest software (Becton Dickinson, 
Franklin Lakes, NJ). The PE-labeled rat antibodies against mouse CD3, CD138, 
CD23 and IgD, the FITC-labeled rat antibodies against mouse B220, CD21 and IgM, 
and APC-labeled rat antibody against mouse B220 were obtained from BD 
Pharmingen (San Diego, CA). 
 
Cell culture of B cells. B220+ cells (2 × 105) were plated in triplicate on 96-well plates 
before stimulation with lipopolysaccharide (LPS; 10 μg/ml; Sigma) and anti-mouse 
CD40 (1 μg/ml; BD Pharmigen). After 16 hr of stimulation, the viable cell number was 
determined using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI). Aliquots of 40 μl of CellTiter 96® Aqueous One Solution were 
added to each well and incubated for an additional 3 hrs before the final absorbance 
at 490 nm was determined. 
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Measurement of serum immunoglobulins, paraprotein determination and X-Ray 
analysis. The amounts of IgG, IgM, and IgA were determined by ELISA, as described 
previously (21). Paraproteins (M spikes, extra gradients) were determined by SRL, Inc. 
(Tokyo, Japan). X-ray analysis of bones was performed using a Faxitron X-ray 
Specimen Radiographic System (Lincolnshire, IL) and Kodak X-OMAT-TL film 
(Rochester, NY).  
 
Histopathologic analysis. Each mouse was bled under ether anesthesia. At autopsy, 
organs were fixed with 10% formalin in 0.01 M phosphate buffer (pH 7.2) and 
embedded in paraffin. Sections were stained with Hematoxylin and Eosin (H&E) and 
Periodic acid-Schiff (PAS) stain for histopathologic examination by light microscopy. 
For dual immunofluorescent staining, the rabbit antibody against mouse c-Maf, 
FITC-labeled goat anti-rabbit IgG (green), and PE-labeled rat anti-mouse CD138 
antibody (red) were used. The anti-CD138 and anti-B220 antibodies were purchased 
from BD Pharmingen. The immunohistochemical analysis of CD138 and anti-B220 
were performed by the avidin-biotin-peroxidase complex staining technique. For 
immunofluorescent analysis, frozen sections were stained with FITC-labeled goat 
antibodies against mouse immunoglobulins IgG, IgM, IgA, kappa light chain, and 
lambda light chain (ICN Pharmaceuticals, Cleveland, OH).  
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Quantitative reverse transcription-PCR. Total RNA (1 µg) was reverse transcribed 
into cDNA. Each reaction was done in duplicate. The quantity of cDNA in each sample 
was normalized to the amount of hprt cDNA. For the PCR, we used SYBR® Premix Ex 
Taq™ II (TAKARA Bio, Shiga, Japan) according to the manufacturer's instructions. 
The amplification was carried out in a Thermal Cycler Dice® Real Time System 
(TAKARA Bio). The following primer pairs were used: c-Maf forward: 
5'-CTGCCGCTTCAAGAGGGTGCAGC-3' and c-Maf reverse: 
5'-GATCTCCTGCTTGAGGTGGTC-3'; Cyclin D2 forward: 
5'-CCTCTTCTTCACACTTTTGTTGGTC-3' and Cyclin D2 reverse: 
5'-CTACCTCCCGCAGTGTTCCT-3'; Integrin β7 forward: 
5'-CAACCTGGACTCACCCGAAG-3' and Integrin β7 reverse: 
5'-CTACCTCCCGCAGTGTTCCT-3'; Prdm1 forward: 
5'-AAGCCGAGGCATCCTTACC-3' and Prdm1 reverse: 
5'-GTCCAAAGCGTGTTCCCTTC-3'; Pax5 forward: 
5'-ACAAACGCCAAAACCCTACC-3' and Pax5 reverse: 
5'-CTGCTGTACTTTTGTCCGAATGA-3'; Xbp1 forward: 
5'-GGAGCAGCAAGTGGTGGATT-3' and Xbp1 reverse: 
5'-CAGCGTGTCCATTCCCAAG-3': c-Myc forward: 5'-GATTTCCTTTGGGCGTTGG-3' 
and c-Myc reverse: 5'-GAGGTCATAGTTCCTGTTGGTGAAG-3'; Irf4 forward: 
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5'-GGTGTACAGGATTGTTCCAGAGG-3' and Irf4 reverse: 
5'-GCAGAGAGCCATAAGGTGCTG-3'; Spp1 forward: 
5'-GCTTGGCTTATGGACTGAGGT-3' and Spp1 reverse: 
5'-TCAGAAGCTGGGCAACAGG-3'; Hprt forward: 
5'-TTGTTGTTGGATATGCCCTTGACTA-3' and Hprt reverse: 
5'-AGGCAGATGGCCACAGGACTA-3'.  
 
Statistical analysis. Results were expressed as the mean ± SE. Data were 
compared by one-way analysis of variance (ANOVA) and the Bonferroni correction 
was applied routinely. Significant differences between the groups of mice were 
analyzed using the Wilcoxon test for paired samples, and values of p<0.05 were 
considered statistically significant. Survival rates were compared using the 
Kaplan-Meier method. 
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Results 
 
Generation of Eμ c-Maf transgenic mice that express c-Maf specifically in B 
cells. To generate transgenic mice that express high levels of c-Maf specifically in B 
cells, the murine c-Maf coding sequence was inserted into a vector that contained the 
VH gene promoter, an Eμ enhancer sequence, and a 3' Eκ enhancer sequence (Fig. 
1A). We generated two constructs (the first did not contain the 3' Eκ enhancer) and 
obtained 17 F0 transgenic mice with a BDF1 or C57BL/6J genetic background. 
Subsequently, three transgenic mouse lines with a C57BL/6J genetic background 
were generated, and screened by PCR using tail DNA as the template. Genomic DNA 
was analyzed by Southern blotting to confirm the integrity and copy number of the 
transgene in each transgenic line. The EcoR I/ Hind III fragment that contained the 
c-Maf transgene was 1.3 kb in length, whereas the corresponding fragment for the 
endogenous c-Maf gene was 4.0 kb. The results of densitometric analyses revealed 
that TG (transgenic) line 524, which was generated using construct-1, contained 
approximately four copies of the transgene, whereas TG lines 99 and 68, which were 
generated with construct-2, both contained approximately two copies (Fig. 1B, a). 
These transgenes were stably transmitted to the progeny. 
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Overexpression of c-Maf in transgenic mice. To confirm that the transgene was 
expressed, the levels of c-Maf mRNA and protein in splenic B cells from the TG lines 
were monitored by RT-PCR and western blotting (Fig. 1B, b and c). The c-Maf mRNA 
was overexpressed in all the transgenic mice that were tested (Fig. 1B, b). 
Correspondingly, western blot analysis of B220+ splenic B cells confirmed that the 
levels of c-Maf protein were elevated (Fig. 1B, c). c-Maf protein was not detected in 
wild-type B cells in this analysis.  
 
B cell development and proliferative potential in Eμ c-Maf transgenic mice. To 
investigate the effect of c-Maf overexpression on B-cell differentiation, we carried out 
flow cytometric analysis of splenocytes isolated from transgenic mice at 20 weeks of 
age. Flow cytometry showed that the total numbers of T cells (CD3+) and B cells 
(B220+) in the spleens of Eμ c-Maf transgenic mice were unaltered relative to 
wild-type mice (Fig. 1C). In addition, we could not find any apparent differences in the 
subpopulations of B cells, namely follicular cells (B220+ CD23high CD21-) and marginal 
zone (MZ) B cells (B220+ CD23− CD21high) (Fig. 1C). Next, we analyzed the 
proliferative potential of wild-type and Eμ c-Maf transgenic B cells in vitro. The 
proliferative potential of Eμ c-Maf transgenic B cells was relatively high, but there was 
no substantial difference in the response to LPS (Fig. 1D) or CD40 (data not shown) 
between the two groups.  
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Aged Eμ c-Maf transgenic mice developed lymphoma. The Eμ c-Maf transgenic 
mice appeared healthy up to 50 weeks of age. However, they subsequently developed 
tumors. The mean age at diagnosis as lymphoma by histological analysis was 80.1 
weeks. We confirmed that 28% (18/64) of the Eμ c-Maf transgenic mice developed 
lymphoma (Fig. 2A). We could not detect any apparent difference in survival between 
the mice that were generated with the two different constructs, construct-1 for TG524, 
and construct-2 for TG 99 and 68.  
 
Lymphomas observed in Eμ c-Maf transgenic mice were of B-cell origin. Eμ 
c-Maf transgenic mice appeared healthy up to 50 weeks of age, but they developed 
tumors subsequently. We performed histological analysis to identify the origin of the 
lymphoma cells. The spleens of the Eμ c-Maf transgenic mice were enlarged 
approximately two- to five-fold relative to those of the wild-type mice. The spleens of 
the mice with lymphoma were infiltrated by numerous cells, which partially destroyed 
the normal tissue architecture (Fig. 2B). Cells that had infiltrated demonstrated 
plasma cell-like morphology (Fig. 2B). Moreover, immunohistochemical analysis 
revealed that the infiltrating cells were B220+ (Fig. 2C), and also expressed CD138 
(Fig. 2C). We confirmed that the infiltrating cells were positive for both CD138 and 
c-Maf by immunofluorescence staining (Fig. 2C). To investigate the characteristics of 
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the lymphoma cells, we performed flow cytometry (Fig. 2C and D). We found the 
number of B220+ CD138+ CD21+ CD23+ IgM+ IgD- cells was increased in the 
transgenic mice relative to the wild-type mice. We also found that the number of 
mature plasma cells (B220low CD138+) was increased in the transgenic mice (Fig. 2C).  
 
Hypergammmaglobulinemia in aged Eμ c-Maf transgenic mice. Approximately 
50% (7/14) of the Eμ c-Maf transgenic mice of line 524 showed a clonal M spike in the 
serum between 20 and 50 weeks of age (Fig. 3A). At 120 weeks old, 35% (5/14) of 
these transgenic mice had developed lymphoma. The remaining mice that showed a 
clonal M spike (2/14) demonstrated no evidence of lymphoma at 120 weeks. The 
plasma levels of both IgG and IgM, as measured by ELISA, were increased 
significantly in aged Eμ c-Maf transgenic mice (Fig. 3B). The mean amount of total 
IgG in the transgenic mice was 1760 ± 302 (mg/dl), whereas in the control mice this 
value was 934 ± 142 (mg/dl) (p<0.05). In addition, the mean amount of total IgM in the 
transgenic mice was 1083 ± 223 (mg/dl), whereas in the control mice this value was 
564 ± 92 (mg/dl). However, there was no obvious elevation of total IgA in the 
transgenic mice. It must be noted that only one out of the 14 mice showed high levels 
of both IgG and IgM (Fig. 3B). Notably, these changes in the serum were associated 
with increased numbers of mature plasma cells (B220low CD138+) in the bone marrow; 
the proportion of plasma cells as a percentage of the total number of bone marrow 
 15 
cells was 5–20% in the transgenic mice compared to <5% in the non-transgenic 
controls (Fig. 3C). We also found the number of B220+ CD138+ cells in the bone 
marrow was increased (Fig. 3C). However, we could not identify any obvious 
osteolytic lesions by X-ray analysis (Fig. 3C).  
 
Eμ c-Maf transgenic mice showed clinical features that resembled those of 
patients with plasma cell disorders. In Eμ c-Maf transgenic mice with 
hyperglobulinemia that were over 60 weeks old, renal tubular casts and tubular 
obstruction were observed (Fig. 4A), which resembled human myeloma kidney 
(so-called cast nephropathy) (22). Moreover, glomerular changes that were 
characterized by mesangial widening due to the deposition of PAS-positive material 
were observed in aged Eμ c-Maf transgenic mice (Fig. 4A); this resembled 
monoclonal immunoglobulin deposition disease (MIDD) (22). These renal lesions 
were similar to the pathologic manifestations that are present in human MM and other 
plasma cell disorders in which the systemic chronic overproduction of 
immunoglobulins and the accumulation of light chains, paraproteins, and other 
immunoglobulin fragments are observed (22). The depositions contained 
immunoglobulin light and heavy chains, which consisted of either polyclonal heavy 
and light chains or clonal IgG or IgM heavy chains and kappa light chains (Fig. 4B).  
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Autonomous proliferation in nude mice of lymphoma cells from Eμ c-Maf 
transgenic mice. To ascertain whether the infiltrating tumor cells in Eμ c-Maf 
transgenic mice could proliferate autonomously, we isolated mononuclear cells from 
the spleens of these mice and injected the isolated cells into nude mice via the tail 
vein (106 cells/mouse). Recipient mice displayed prominent hepatomegaly, 
splenomegaly and/or enlarged lymph nodes throughout their bodies within 12 weeks 
of transplantation. A typical example is shown in Fig. 5A. The tumor cells could also 
be transplanted into syngeneic C57BL/6J mice. To assess clonality, we examined the 
rearrangement of the IgH locus in the c-Maf transgenic lymphoma cells. Southern blot 
analysis was carried out using a murine JH4 probe (Fig. 5B). We extracted DNA from 
the tails, and spleens of the mice. Monoclonal rearrangement of the IgH locus was 
found in DNA that had been isolated from the spleens of the Eμ c-Maf transgenic mice 
(Fig. 5B, lanes 3 to 6). Histological analysis of the spleen from these recipient mice 
revealed that the tumor cells showed a plasma cell-like morphology, i.e. the same as 
the original lymphoma cells (Fig. 5C).  
 
Expression of c-Maf target genes in Eμ c-Maf transgenic mice. To gain insight 
into the molecular mechanism by which plasma cell dyscrasia develops, we measured 
the level of mRNA expression from c-Maf and its target genes in Eμ c-Maf transgenic 
mice using a quantitative RT-PCR assay (Fig. 6). In human MM, CYCLIN D2 and 
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INTEGRIN β7 are known to be targets of c-MAF (7, 23). As we described previously, 
deregulated expression of Cyclin D2 and Integrin β7 is also observed in the T cell 
lymphomas of transgenic mice that overexpress c-Maf in the T lymphoid compartment 
(17). Therefore, we analyzed the expression of Cyclin D2 and Integrin β7 in Eμ c-Maf 
transgenic mice. The level of c-Maf expression in the lymphoma-infiltrated lymph 
nodes of Eμ c-Maf transgenic mice was three- to five-fold greater than the level in 
wild-type B cells (B220+) (Fig. 6). We confirmed the percentage of B220+ cells in the 
lymph nodes was over 70 %. We also found that the expression of both Cyclin D2 and 
Integrin β7 was elevated in Eμ c-Maf transgenic mice (Fig. 6), which was consistent 
with the results of previous reports in human MM (7).  
     Next, we examined the levels of the B cell-associated transcription factors, 
Prdm1 (Blimp-1), Xbp1 and Pax5. Blimp-1 is a transcriptional repressor that plays a 
critical role in the terminal differentiation of B cells into antibody-secreting plasma cells 
(24). Overexpression of Blimp-1 has been shown to drive plasma cell differentiation 
(24-26). Xbp1 is a basic-region leucine zipper (bZIP) transcription factor and a major 
regulator of plasma cell differentiation (27). It is known that Eμ Xbp1s mice develop 
MM/MGUS (28). In addition, Pax5 is known to inhibit plasmacytic development, and 
also to repress the expression of Xbp1, which is needed for plasma cell formation and 
immunoglobulin secretion (29). By RT-PCR analysis (Fig. 6), we found that Prdm1 and 
Xbp1 expression were increased, but Pax5 expression was decreased, in the 
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transgenic mice as compared to the control mice, which might correlate with the 
plasma cell differentiation.  
      It is known that the dysregulation of MYC (c-MYC) expression can induce the 
progression of MGUS to MM (1). In addition, it has been reported that myeloma cells 
are completely dependent on the transcription factor IRF4 (interferon regulatory factor 
4), despite that fact that most myeloma cells do not harbour mutations, translocations 
or amplifications of the IRF4 locus (30). Moreover, IRF4 is itself a direct target of MYC, 
which generates an autoregulatory circuit in myeloma cells (30). However, neither 
Myc nor Irf4 expression were elevated in the Eμ c-Maf transgenic mice. We also 
analyzed Spp1 (osteopontin) expression, because we could not find any obvious 
osteolytic lesions in the Eμ c-Maf transgenic mice. SPP1, which is highly expressed in 
MM, plays a critical role in bone disease by protecting the bone from destruction (31). 
We observed that the expression of Spp1 was up-regulated in Eμ c-Maf transgenic 
mice (Fig. 6). 
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Discussion 
 It is important to emphasize that v-maf is a classical oncogene that was identified 
in an avian transforming virus, AS42 (8). Large Maf proteins, such as c-Maf, Mafb and 
Mafa, can efficiently transform primary fibroblasts in vitro (9, 32-34). Previously, we 
generated c-Maf transgenic mice that overexpress c-Maf in the T-cell compartment 
using the VA vector, which contains the human CD2 promoter and locus control region. 
The VA c-Maf transgenic mice developed T-cell lymphoma, thus providing evidence 
that c-Maf can function as an oncogene in T cells in vivo (17). Work over the last 
decade has provided evidence that c-MAF might play crucial roles in the pathogenesis 
of MM. It has been reported that the translocation and/or overexpression of c-MAF are 
identified frequently in human MM (6, 7, 23). Translocations that involve MAFA (23, 
35) or MAFB (t(14;20)(q32;q12)) (35, 36), which encode other large MAF proteins, 
have also been identified. Altogether, translocations that involve a large MAF 
transcription factor are found in 8−10% of MMs: c-MAF is translocated in 5%, MAFB in 
2%, and MAFA in less than 1% of cases (23, 35). Although c-MAF translocations are 
observed in only 5−10% of MMs, c-MAF is overexpressed in 50% of cases (7, 23).  
 In this study, we demonstrated that aged c-Maf transgenic mice developed B cell 
lymphomas with some clinical features that resembled those of human MM, namely 
expansion of plasma cells, hyperglobulinemia, and renal involvement. Although we 
found that plasma cells (B220low CD138+) were increased in the spleen and bone 
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marrow of the transgenic mice, the lymphoma cells in the spleens were B220+ CD138+ 
CD21+ CD23+ IgM+ IgD-. The phenotype of some Eμ c-Maf transgenic mice partially 
resembled that of types of B cell lymphoma that contain plasmablasts and/or plasma 
cells rather than plasma cell dyscrasias, such as Waldenström's macroglobulinemia 
(WM; also known as lymphoplasmacytic lymphoma) or MALT (mucosa associated 
lymphoid tissue) lymphoma. WM is classified as an indolent form of B-cell lymphoma. 
Infiltration with clonal lymphoplasmacytic cells, predominantly in the bone marrow, 
and an IgM monoclonal gammopathy are diagnostic findings of WM (37). MALT 
lymphoma is a distinct subtype of MZ B cell lymphomas. The large number of plasma 
cells among MALT lymphoma cells is a well known phenomenon known as 
plasmacytic differentiation (38). With the demonstration that the tumors express both 
mature B cell (B220+) and plasma cell (CD138+) markers, it should be noted that they 
fall within a spectrum of mouse plasma cell-related tumors (anaplastic, plasmablastic, 
and plasmacytic plasmacytoma) described, previously (39, 40, 41). The Eμ c-Maf 
transgenic mouse is a murine model of the human MM t(14;16)(q32;q23) 
chromosomal translocation. Primary early onset reciprocal chromosomal 
translocations in MM occur most frequently at IGH on 14q32. Meanwhile, secondary 
late onset translocations and gene mutations have been implicated in MM progression 
(42). The fact that Eμ c-Maf transgenic mice displayed immature phenotypes rather 
than classical MM might suggest that c-MAF translocation alone is not sufficient for 
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the development of classical MM. Experimental efforts to generate mouse models of 
MM have typically involved the targeted expression of an oncogene in the B cell 
compartment by transgenic approaches (28). These strategies have generally yielded 
B cell malignancies that display immature phenotypes or plasmacytomas rather than 
classical MM  (28). Given that c-MAF is known to be translocated and/or 
overexpressed in human MM, the Eμ c-Maf transgenic mouse may offer an ideal 
system to study the pathogenesis of human MM. Aged Eμ c-Maf transgenic mice 
developed B cell lymphomas, rather than plasma cell dyscrasias. In the majority of 
cases, transgenic mice that express an oncogene or proto-oncogene specifically in 
the B cell compartment develop plasmacytoma, not classical MM. This is the case for 
v-abl  (43), Il-6  (44), and Bcl-2/c-Myc (45) mice; however, Eμ Xbp1s (28) transgenic 
mice are the exception. Recently, it was reported that transgenic mice in which the 
c-Myc gene was subject to conditional Aid (Activation-Induced 
Deaminase)–dependent activation developed the MM/MGUS phenotype (46). We do 
not understand the underlying differences in the promotion of tumor formation 
between mice and humans.  
Further studies will be needed to define the role of c-Maf in the development of both 
human and mouse MM. Clarification of the mechanism by which c-Maf contributes to 
oncogenesis may ultimately facilitate the discovery of more specific therapies to 
prevent the progression of MM. 
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Figure legends 
 
Figure 1. Generation of mice that overexpress c-Maf. A, Constructs of the Eμ c-Maf 
transgene. The c-Maf cDNA was inserted into a vector that contained the VH gene 
promoter (Vp), and an Eμ enhancer (Eμ), or one that contained Vp, Eμ, and a 3' Eκ 
enhancer (Eκ). The probe for Southern blot analysis, the restriction enzyme sites 
(EcoR I; E, and Hind III; H), and the predicted sizes of the endogenous gene and the 
transgene are indicated. Transgene construct-1 was used for TG line 524, whereas 
TG lines 99 and 68 were generated with construct-2. B-a, Southern blot analysis of 
the endogenous and transgenic c-Maf genes in Eμ c-Maf transgenic mice. The 4.0-kb 
endogenous and 1.3-kb transgenic gene fragments are shown for TG mice. B-b, 
Analysis of c-Maf mRNA in B cells. The amount of c-Maf mRNA in the samples from 
TG was higher than that in a sample from wild-type (WT) mice. B-c, Western blot 
analysis of splenic B220+ B cells from Eμ c-Maf transgenic mice (524, 99, and 68) and 
wild-type mice (WT). C, Immunofluorescence analysis of splenocyte subpopulations 
from Eμ c-Maf transgenic mice at 20 weeks of age. The total numbers of T cells 
(CD3+) and B cells (B220+) did not differ between the spleens of wild-type and Eμ 
c-Maf transgenic mice. There were no apparent differences in the subpopulations of B 
cells, namely follicular cells (B220+ CD23high CD21-) and marginal zone (MZ) B cells 
(B220+ CD23− CD21high). D, Proliferative potential of B cells after treatment with LPS. 
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Enriched splenic B220+ cell populations obtained from wild-type and Eμ c-Maf 
transgenic mice at 20 weeks of age were cultured in the presence of LPS, and 
proliferation was assayed by using a CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay. The mean absorbance at 490 nm is presented. 
 
Figure 2. Eμ c-Maf transgenic mice developed B cell lymphoma. A, Cumulative 
lymphoma-free survival rate curves of Eμ c-Maf transgenic (TG) and wild-type (WT) 
mice. Statistically significant differences (p<0.05) were detected between the two 
groups. B, The number of plasma cell-like lymphoma cells in the spleens of Eμ c-Maf 
transgenic (TG) mice was increased compared to that in the controls (WT). Disruption 
of the normal follicules and accumulation of lymphoma cells were observed in spleens 
from the transgenic mice (H&E). C, The B cell lymphoma cells (B220+) also expressed 
CD138, as shown by immunohistochemical staining of B220 and CD138. 
Immunofluorescence showed that plasma cells (CD138+, red) that had infiltrated into 
the spleens of Eμ c-Maf transgenic mice also expressed c-Maf (green), but this was 
not observed in the spleens of wild-type mice. Flow cytometry revealed that the 
number of B220+ CD138+ cells was increased in the spleens of Eμ c-Maf transgenic 
mice that carried lymphoma. The number of mature plasma cells (B220low CD138+) in 
the spleen was also increased. D, B220+ CD138+ cells in the spleens of Eμ c-Maf 
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transgenic mice were characterized as B220+ CD138+ CD21+ CD23+ IgM+ IgD- by flow 
cytometry.  
 
Figure 3. Hypergammaglobulinemia, bone marrow plasmacytic infiltration, and X-ray 
analysis of the bones in Eμ c-Maf transgenic mice. A, Representative results of 
electrophoresis of the serum proteins. Note the presence of an M spike (arrow) in Eμ 
c-Maf transgenic mice at 50 weeks old. B, Marked elevation of serum immunoglobulin 
levels in Eμ c-Maf transgenic mice. Sera from wild-type ( ; n=7) and Eμ c-Maf 
transgenic ( ; n=14) mice at 50 weeks old were analyzed by ELISA (upper panel). 
The plot shows both IgG and IgM levels in Eμ c-Maf transgenic mice at 50 weeks old. 
Only one out of the 14 mice showed high levels of both IgG and IgM (lower panel). C, 
Representative bone marrow biopsies from wild-type (WT) and Eμ c-Maf transgenic 
(TG) mice were analyzed by light microscopy (H&E) to reveal increased plasma cell 
infiltrates in the marrow of Eμ c-Maf transgenic mice. FACS analysis also revealed 
that the numbers of mature plasma cells (B220low CD138+) and B220+ CD138+ cells 
were increased in the bone marrow in the transgenic mice. Obvious osteolytic lesions 
could not be found in 50 weeks old Eμ c-Maf transgenic mice by X-ray analysis.  
 
Figure 4. Renal involvement in Eμ c-Maf transgenic mice. A, Renal tissue sections 
from 60 weeks old Eμ c-Maf transgenic (TG) mice with lymphoma and wild-type (WT) 
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mice were stained with PAS. Left panels show renal tubules, whereas right panels 
represent glomeruli. B, Glomerular immunoglobulin deposition. Serial frozen sections 
of renal tissue from wild-type and Eμ c-Maf transgenic mice were analyzed by 
immunofluorescent staining using specific antibodies against mouse immunoglobulin 
kappa and lambda light chains, as well as antibodies against IgG, IgM, and IgA heavy 
chains..  
 
Figure 5. Autonomous proliferation of c-Maf-induced lymphoma cells. A, Mononuclear 
cells that had been isolated from the spleens of Eμ c-Maf transgenic mice and 
transplanted into nude mice infiltrated the spleens of the recipient mice. Enlarged liver 
and spleen were observed in the recipient mouse. B, Southern blot analyses of 
lymphoma cells from the spleens of Eμ c-Maf transgenic mice using a JH4 probe after 
digestion with EcoR I. Lane 1 (DNA from tail of a wild-type mouse), lane 2 (DNA from 
the tail of an Eμ c-Maf transgenic mouse), and lanes 3 to 6 (DNA from the enlarged 
spleens from Eμ c-Maf transgenic mice) show the presence of a DNA fragment 
corresponding to the germ line JH4 gene (solid arrow). Lanes 3 to 6 show DNA 
fragments that corresponded to rearrangements of the IgH gene (asterisk). Lanes 2 to 
6 show a DNA fragment that corresponded to the IgH transgene (hollow arrow). C, 
Transplanted tumor cells showed a plasma cell-like appearance in the spleens of the 
recipients, as shown by H&E staining.  
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Figure 6. Analysis of c-Maf target genes by quantitative RT-PCR. The expression 
profiles of Maf (c-Maf) and its target genes were examined by real-time RT-PCR 
analysis. Total RNA was obtained from the enlarged lymph nodes from Eμ c-Maf 
transgenic mice. All of the data are presented as the mean ± SE. , WT; mRNA from 
B220+ B cells from the spleens of 50 weeks old wild-type mice, , TG; mRNA from 
the lymph nodes of mice from Eμ c-Maf TG line 524. * indicates p<0.05.  
 






